Search - tctmd.com

Displaying 1 - 20 of 101

Sort: Relevancy | Date

News Daily News

Andexanet Alfa Pulled From US Market

Todd Neale

December 22, 2025

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

Aortic Stenosis Slowed by SGLT2 Inhibitors in Observational Study

Yael L. Maxwell

February 20, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

L.A. McKeown

December 23, 2024

News Daily News

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

L.A. McKeown

August 21, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

Biologic Winrevair Wins FDA Approval for Treatment of PAH

L.A. McKeown

March 27, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

Todd Neale

March 08, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

Advertisement

Andexanet Alfa Pulled From US Market

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

FDA Approves Triple Therapy Polypill for High Blood Pressure

Aortic Stenosis Slowed by SGLT2 Inhibitors in Observational Study

January 2025 Dispatch for the CV Team

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Biologic Winrevair Wins FDA Approval for Treatment of PAH

Bempedoic Acid Gains CV Risk Reduction Indication

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

FDA Grants MACE Reduction Indication for Semaglutide

TCTMD’s Top 10 Most Popular Stories for December 2023

Top Endovascular News of 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

FDA Grants Tirzepatide a New Indication for Obesity Management

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content